timm8a Antibody

What is TIMM8A and why is it relevant to cancer research?

TIMM8A is a protein-coding gene located on the X chromosome that produces Tim8a protein. It functions in the intermembrane space of mitochondria, forming a complex with Tim13 to act as a chaperone facilitating the import of nuclear-encoded precursor proteins into the inner mitochondrial membrane . Research shows TIMM8A plays an important role in mitochondrial morphology and fission . Its relevance to cancer research stems from findings that TIMM8A is significantly upregulated in breast cancer tissues compared to normal tissues, and this upregulation correlates with poor prognosis . The mRNA expression of TIMM8A in breast cancer tissues (n=1109) is significantly higher than in normal tissues (n=113) (3.391±0.636 vs 3.005±0.618, P<0.001) .

How should researchers validate TIMM8A antibody specificity?

For rigorous validation of TIMM8A antibodies, researchers should implement a multi-faceted approach:

• Perform comparative analyses using multiple antibodies targeting different TIMM8A epitopes

• Include appropriate positive controls (breast cancer tissues showing TIMM8A upregulation)

• Test in TIMM8A-knockout or knockdown models as negative controls

• Conduct peptide competition assays where the antibody is pre-incubated with the immunizing peptide

• Verify staining patterns match the expected mitochondrial localization pattern

• Compare antibody reactivity with mRNA expression data from matching samples

• Test for cross-reactivity with other TIM family proteins, particularly those with similar structural domains

What expression patterns of TIMM8A should researchers expect in normal vs. cancer tissues?

Based on comprehensive analyses, researchers should expect:

• Significantly higher TIMM8A expression in breast cancer tissues compared to adjacent normal tissues

• Paired data analysis showing TIMM8A mRNA expression levels significantly higher in breast cancer tissues (3.351±0.597) than in adjacent normal tissues (2.998±0.617, P<0.001)

• Human Protein Atlas immunohistochemistry data confirming upregulated TIMM8A protein expression in breast cancer tissues

• Expression levels that increase with cancer stage in UCEC, and a similar trend in breast cancer (with the exception of stage 3)

• Correlation between TIMM8A expression and hormone receptor status in breast cancer, with significant differences observed in PR status (P<0.001), ER status (P<0.001), and HER2 status (P=0.014)

What are optimal methods for detecting TIMM8A in various experimental contexts?

The optimal detection methods depend on your research objectives:

How does TIMM8A expression correlate with immune cell infiltration in cancer?

TIMM8A expression demonstrates complex associations with immune infiltration that differ between cancer types:

In breast cancer, TIMM8A expression shows significant positive correlations with:

• B cells (r=0.174, P=3.43e−08)

• Th2 CD4+ T cells (r=0.564, P=1.89e−84)

• CD8+ T cells (r=0.147, P=3.02e−06)

• Dendritic cells (r=0.163, P=2.31e−07)

• Macrophages (r=0.254, P=4.83e−16)

• Neutrophils (r=0.313, P=4.57e−24)

In UCEC, TIMM8A shows different patterns, with:

• Positive correlation with Th2 CD4+ T cells (r=0.329, P=1.78e−03)

• Negative correlation with CD8+ T cells (r=−0.416, P=5.61e−05)

• Negative correlation with macrophages (r=−0.338, P=1.30e−03)

• Negative correlation with NK cells (r=−0.247, P=2.01e−02)

These differential correlations may explain the distinct prognostic implications of TIMM8A in these cancers.

What methodological approaches should be used to study TIMM8A's relationship with immunotherapy response?

When investigating TIMM8A's role in immunotherapy response, researchers should:

• Perform multiplex immunofluorescence staining to co-localize TIMM8A with immune checkpoint proteins (PD-L1, CTLA-4)

• Analyze correlations between TIMM8A expression and known predictive biomarkers of immunotherapy response

• Examine TIMM8A expression in pre- and post-treatment samples from patients receiving immune checkpoint inhibitors

• Conduct functional studies using TIMM8A knockdown/overexpression in cancer cell lines treated with checkpoint inhibitors

• Analyze the relationship between TIMM8A and immune cell exhaustion markers

Research has shown significant positive correlations between TIMM8A expression and immune checkpoint molecules including PD-L1 and CTLA-4 in breast cancer . TIMM8A could potentially serve as a biomarker predicting efficacy of anti-PD-L1 therapy, with better predicted outcomes in breast cancer than in UCEC .

How can researchers investigate the relationship between TIMM8A and methylation in cancer?

The search results indicate that methylation at seven CpG sites in TIMM8A (cg01062269, cg24976080, cg19680277, cg21411942, cg19014767, cg16245086, and cg08358587) is associated with prognosis . To investigate this relationship:

• Use methylation-specific PCR targeting these specific CpG islands

• Perform bisulfite sequencing for comprehensive methylation analysis

• Conduct methyl-DNA immunoprecipitation (MeDIP) followed by qPCR for the regions of interest

• Correlate methylation data with protein expression using TIMM8A antibodies

• Compare methylation patterns across different cancer stages and molecular subtypes

• Integrate methylation data with transcriptome and proteome analyses

What are the optimal antibody approaches for studying TIMM8A in mitochondrial dynamics?

When investigating TIMM8A's role in mitochondrial dynamics:

• Select antibodies that specifically recognize TIMM8A without cross-reacting with other TIM family proteins

• Perform co-immunoprecipitation studies to detect interactions with:

  • Tim13 (known binding partner)

  • DRP1 (mitochondrial fission protein)

  • Other mitochondrial import machinery components

• Use proximity ligation assays to confirm protein-protein interactions in situ

• Implement live-cell imaging with fluorescently tagged antibodies or TIMM8A constructs

• Combine with mitochondrial morphology assessment using established markers (MitoTracker, TOM20)

• Correlate findings with functional readouts of mitochondrial fission rates

Research indicates that TIMM8A can enhance mitochondrial fission efficiency by binding to DRP1 . Increased expression of DRP1 protein in breast cancer is directly proportional to cancer invasiveness and metastasis .

How should researchers interpret discrepancies between TIMM8A antibody detection and mRNA expression data?

When faced with discrepancies between protein and mRNA data:

• Consider post-transcriptional regulation mechanisms affecting TIMM8A

• Validate antibody specificity using multiple detection methods and controls

• Examine potential protein degradation during sample preparation

• Investigate half-life differences between TIMM8A mRNA and protein

• Explore the impact of mitochondrial stress on TIMM8A expression and stability

• Analyze potential alternative splicing that might affect epitope availability

• Perform time-course studies to capture temporal differences in expression

In the novel TIMM8A variant (c.1A>T, p.Met1Leu) reported in DDON syndrome, researchers found no detectable protein despite the presence of transcript, although at reduced levels . This example highlights how mutations can affect post-transcriptional regulation of TIMM8A.

What are the critical factors for successful TIMM8A immunoprecipitation?

For optimal TIMM8A immunoprecipitation:

• Begin with mitochondrial isolation to enrich the starting material

• Test different lysis buffers optimized for mitochondrial intermembrane space proteins

• Consider crosslinking approaches if studying transient interactions

• Use antibodies targeting epitopes that are accessible in the native protein conformation

• Include appropriate controls:

  • IgG control

  • Input sample

  • TIMM8A-depleted or overexpressed samples

• Validate results with reciprocal co-IP when studying protein-protein interactions

• Confirm specificity through mass spectrometry identification of precipitated proteins

This approach is particularly valuable when investigating TIMM8A interactions with Tim13 and potential associations with immune signaling proteins.

What epitope considerations are important when selecting TIMM8A antibodies?

When selecting or designing antibodies against TIMM8A:

• Target the small-twin CX₃C motif which is characteristic and functionally important

• Avoid transmembrane regions which may be inaccessible in native conformations

• Consider epitopes that would distinguish TIMM8A from other TIM family proteins

• For detecting specific mutations (like the c.1A>T variant), design epitopes spanning the mutation site

• Choose peptides conserved across species if cross-reactivity is desired

• Select surface-exposed regions based on protein structure prediction

• Consider the intact protein conformation in the Tim8a-Tim13 complex

What fixation and antigen retrieval protocols optimize TIMM8A detection in tissues?

Based on research experience with mitochondrial proteins:

For antigen retrieval:

• Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes provides good results

• Alternative: EDTA buffer (pH 9.0) for some antibody clones

• Always validate with positive controls (breast cancer tissue with known TIMM8A expression)

• Consider dual immunofluorescence with mitochondrial markers to confirm localization

How can researchers optimize flow cytometry protocols for TIMM8A detection?

For successful flow cytometry applications with TIMM8A antibodies:

• Permeabilization optimization is critical:

  • Test gentle detergents (0.1% Triton X-100, 0.1% Saponin)

  • Consider specialized mitochondrial permeabilization reagents

  • Validate with known mitochondrial proteins

• Staining protocol:

  • Fix cells with 2-4% paraformaldehyde

  • Permeabilize with optimized buffer

  • Block with 5% normal serum

  • Incubate with primary antibody at optimized concentration

  • Apply fluorophore-conjugated secondary antibody

  • Include proper compensation controls

• Validation approaches:

  • Compare with western blot results

  • Test in TIMM8A knockdown models

  • Perform imaging flow cytometry to confirm subcellular localization

What are the recommended approaches for multiplexed detection of TIMM8A with immune markers?

For multiplexed detection:

• Select compatible antibody pairs:

  • Primary antibodies raised in different host species

  • Directly conjugated antibodies with non-overlapping fluorophores

  • Validate each antibody individually before multiplexing

• Optimized methods include:

  • Sequential immunofluorescence staining

  • Tyramide signal amplification for weak signals

  • Spectral imaging to resolve overlapping fluorophores

  • Multiplex immunohistochemistry platforms (e.g., Opal, CODEX)

• Analysis considerations:

  • Use appropriate controls for each marker

  • Implement spectral unmixing for overlapping fluorophores

  • Quantify co-localization using established metrics (Pearson's coefficient)

  • Perform spatial analysis of TIMM8A in relation to immune cell markers

This approach is particularly valuable when investigating relationships between TIMM8A and immune checkpoint molecules like PD-L1 and CTLA-4 .

How can TIMM8A antibodies be used to investigate its potential as a therapeutic target?

TIMM8A's emerging role as a potential therapeutic target can be investigated by:

• Using antibodies to screen for compounds that modulate TIMM8A expression or function

• Developing assays to measure TIMM8A-specific activity in response to candidate drugs

• Performing target engagement studies with therapeutic candidates

• Evaluating TIMM8A expression before and after treatment with existing drugs

• Investigating the 15 small molecular drugs identified to target TIMM8A, including Cyclosporine, Leflunomide, and Tretinoin

The CTD database analysis identified these compounds as potentially effective therapies for targeted inhibition of TIMM8A, which could be valuable in treating TIMM8A-overexpressing cancers .

What methodological approaches can resolve contradictory findings about TIMM8A's role in different cancer types?

To address contradictory findings:

• Implement tissue-specific controls and standardized antibody validation protocols

• Perform comprehensive isoform-specific analyses

• Consider cancer subtype-specific effects through stratified analyses

• Investigate context-dependent protein interactions using proximity ligation assays

• Conduct parallel studies in multiple cancer types using identical methodologies

• Evaluate TIMM8A function in relation to the tumor microenvironment

• Integrate multi-omics approaches to understand regulatory networks

The contrasting correlations between TIMM8A and immune cell infiltration in BRCA versus UCEC highlight the importance of context-specific analyses .

How should researchers analyze the relationship between TIMM8A and mitophagy in immune cells?

To investigate TIMM8A's impact on mitophagy and immune function:

• Use dual labeling with TIMM8A antibodies and mitophagy markers (PINK1, Parkin)

• Implement live-cell imaging to track mitochondrial dynamics in immune cells with varying TIMM8A expression

• Analyze mitophagy flux in immune cells after manipulating TIMM8A expression

• Correlate TIMM8A expression with mitochondrial mass and membrane potential

• Investigate relationships between TIMM8A and mitophagy regulatory proteins

Research indicates that in breast cancer, TIMM8A expression negatively correlates with PINK1 and Parkin, while in UCEC, Parkin shows negative correlation with TIMM8A . This suggests TIMM8A may affect immune infiltration by inhibiting mitophagy, thus promoting immune cell apoptosis and potentially contributing to tumorigenesis .

What is the significance of TIMM8A methylation in cancer prognosis and how can it be studied?

The methylation of TIMM8A has significant prognostic implications:

To study this relationship:

• Implement methylation-specific PCR targeting these CpG islands

• Perform bisulfite sequencing for comprehensive methylation analysis

• Correlate methylation patterns with protein expression using antibodies

• Examine the effect of demethylating agents on TIMM8A expression and function

• Integrate methylation data with clinical outcome information

How can researchers design experiments to clarify TIMM8A's role in immune checkpoint regulation?

Based on TIMM8A's correlations with immune checkpoint molecules:

• Design co-culture experiments with:

  • TIMM8A-modulated cancer cells

  • Immune cells expressing checkpoint receptors

  • Checkpoint inhibitor treatments

• Implement analytical approaches:

  • Flow cytometry to quantify checkpoint expression

  • Functional assays measuring T cell activation and tumor cell killing

  • Proximity ligation assays to detect potential physical interactions

  • RNA-seq to assess transcriptional effects of TIMM8A on checkpoint pathways

• In vivo approaches:

  • Generate TIMM8A knockout or overexpression models

  • Test response to checkpoint inhibitors

  • Analyze immune infiltration profiles

  • Measure tumor growth in immunocompetent vs. immunodeficient backgrounds

Research has shown significant positive correlations between TIMM8A and immune checkpoint molecules including PD-L1 and CTLA-4 in breast cancer , suggesting potential applications in predicting and improving immunotherapy response.